Labcorp has launched nationwide access to Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic for identifying platinum-resistant ovarian cancer patients eligible ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

With the acquisition of BioVectra and a growing focus on advanced therapeutics, the company is positioning itself differently ...

Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core (1) basis compared with the third quarter ...

Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, provides application focused solutions to the life ...

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active ...

Over the past six months, Agilent’s stock price fell to $118.28. Shareholders have lost 16.7% of their capital, which is ...

Agilent Technologies Inc. has announced the launch of its new Insight Series Alarm Resolution Systems, designed to enhance safety and streamline operations at airport security checkpoints worldwide.

Agilent stands out as a focused, well-managed leader in life science instruments, with strong financials and resilience amid global trade headwinds. The Ignite transformation program enhances supply ...

Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be ...

Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests ...

Agilent is a wonderful business with a strong competitive moat, decent growth, and excellent profitability. The company benefits from customer "stickiness" and growth in the biopharmaceutical sector.